Full Breakdown
Breakthrough Gene Therapy Offers Hope for Children with ADA-SCID
10/16/2025, 12:49:18 PM
Life-Changing Results for Patients
A groundbreaking gene therapy has shown remarkable success in treating children with adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID), a rare and life-threatening genetic disorder. This innovative treatment, developed by an international team including researchers from Great Ormond Street Hospital (GOSH), University College London (UCL), and the University of California, Los Angeles (UCLA), has restored immune function in 59 of 62 children treated between 2012 and 2019, achieving a 95% success rate with no serious complications reported.
ADA-SCID is caused by mutations in the ADA gene, which is crucial for immune system function. Without treatment, children with this condition face severe infections and typically do not survive beyond their second birthday. Traditional therapies, such as bone marrow transplants and enzyme replacement, carry significant risks and logistical challenges. The new gene therapy involves harvesting a child's blood stem cells, modifying them in a laboratory to include a healthy copy of the ADA gene using a lentiviral vector, and then reinfusing these corrected cells back into the patient.
Clinical Trial Insights
The study, published in the *New England Journal of Medicine*, represents the largest and longest follow-up of gene therapy for ADA-SCID, with an average follow-up of 7.5 years. The results indicate that all treated children survived, and the majority have been able to discontinue enzyme replacement therapy and respond positively to routine vaccinations. The therapy's success is attributed to its ability to engraft effectively and maintain immune function over time.
Professor Donald Kohn, a leading researcher in the study, emphasized the significance of these findings, stating, “The durability of immune function, the consistency over time, and the continued safety profile are all incredibly encouraging.” The study also validated the use of cryopreservation techniques for the gene-corrected stem cells, which could enhance accessibility for patients worldwide by allowing for local collection and centralized processing.
Patient Experiences
Among the children treated is nine-year-old Andy Cash from Portlaoise, Ireland, who was diagnosed with ADA-SCID at three weeks old. After undergoing the gene therapy at GOSH, Andy has thrived, engaging in activities like boxing and attending school with his siblings. His mother, Mary Cash, expressed gratitude for the treatment, noting, “It’s been life-changing. He’s full of energy and makes friends wherever he goes.”
Similarly, Eliana Nachem, diagnosed with ADA-SCID at three months old, received the gene therapy at ten months. Now eleven years old, she enjoys a normal childhood, participating in school and sports, a stark contrast to her previous life in isolation due to her condition. Her mother, Caroline, remarked on the transformation, stating, “It’s amazing that she was able to go from living in isolation to being able to go to preschool and play on a playground.”
Future Prospects
The research team is now preparing to seek regulatory approval from the U.S. Food and Drug Administration (FDA) for the gene therapy, with hopes of making it publicly available within the next two to three years. This advancement could significantly improve the lives of children with ADA-SCID and pave the way for similar treatments for other rare genetic disorders.
As the medical community anticipates the potential approval, the success of this gene therapy stands as a testament to the collaborative efforts of researchers, healthcare providers, and families, offering hope for a brighter future for children affected by ADA-SCID and beyond.
